Janux Therapeutics Ownership

Janux Therapeutics has a total of 52.48 Million outstanding shares. The majority of Janux Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Janux Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Janux Therapeutics. Please pay attention to any change in the institutional holdings of Janux Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million two hundred seventeen thousand five hundred eighty-two invesors are currently shorting Janux Therapeutics expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as Janux Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Janux Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Dividend Paid And Capex Coverage Ratio is likely to drop to -28.7 in 2024. Common Stock Shares Outstanding is likely to rise to about 46.2 M in 2024, despite the fact that Net Loss is likely to grow to (53.9 M). Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.